Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dihydroartemisinin-piperaquine for uncomplicated Plasmodium falciparum malaria in Pakistan
ACTRN12615001248550Phase 4Completed
- Sponsor
- Directorate of Malaria Control
- Start
- Oct 2015
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of dihydroartemisinin and piperaquine in Malaria, sponsored by Directorate of Malaria Control. Primary endpoints: Treatment failure rate, Adequate clinical and parasitological response and 2 more. Started Oct 2015; status: completed.
02
Drugs
dihydroartemisininpiperaquine
03
Conditions
Malaria
Beyond the preview
Go deeper on ACTRN12615001248550.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12615001248550.